Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of stathmin as a biomarker of drug response to furazanobenzimidazoles

Use of stathmin as a biomarker of drug response to furazanobenzimidazoles

US Patent 9366682 · Granted Jun 14, 2016

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Pharmaceutical combinations for use in the treatment of neoplastic diseases2022
Pharmaceutical combinations for use in the treatment of neoplastic diseases2022
Use of phospho-Akt as a biomarker of drug response2020
Use of phospho-Akt as a biomarker of drug response2020
Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles2020
Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles2020
Substituted mono- and polyazanaphthalene derivatives and their use2019
Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles2019
Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles2019
Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazo2018
Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazo2018
Use of phospho-Akt as a biomarker of drug response2018